Osteoporosis is a progressive bone disease characterized by low bone mass that increases bone fragility leading to an increase in fracture risk.^[@bibr1-2381468318818843]^ Osteoporosis can be diagnosed either by the presence of fragility fractures or based on the World Health Organization criteria relating to bone mass: having a bone mineral d*e*nsity (BMD) that is at least 2.5 standard deviations (SD) below the mean peak bone mass of an average young female.^[@bibr2-2381468318818843]^ In Canada, the prevalence of osteoporosis in postmenopausal women increases from approximately 6% in those aged 50 to 59 years to over 40% in those aged over 80.^[@bibr3-2381468318818843]^

The most common fractures associated with osteoporosis are fractures of the hip, vertebrae, or wrist. The major source of morbidity from osteoporosis arises from hip fractures, which are also associated with higher costs and greater mortality.^[@bibr4-2381468318818843],[@bibr5-2381468318818843]^ Alongside the increasing prevalence of osteoporosis, the risk of fracture for an osteoporotic women increases with age.^[@bibr3-2381468318818843],[@bibr6-2381468318818843]^ Fracture risk is also related to previous history of fracture and the degree of low bone mass.^[@bibr2-2381468318818843],[@bibr7-2381468318818843]^

The annual health care cost in 2010 associated with osteoporosis in Canada was CAN\$2.3 billion with an additional CAN\$1.6 billion for associated use of long-term care facilities.^[@bibr4-2381468318818843]^ The cost of treating hip fractures comprised more than half of the acute care costs associated with osteoporosis.^[@bibr4-2381468318818843]^ Pharmacological treatments for osteoporosis covered in Ontario, the most populous of Canadian provinces, are bisphosphonates (alendronate, etidronate, risedronate, and zoledronate) and the RANKL (receptor activator of nuclear factor kappa-B ligand) inhibitor---denosumab. The annual costs of osteoporosis drug treatments vary considerably although such costs may by partly offset by reducing the economic burden of fracture.

In April 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released the 4th edition of the Canadian Guidelines for the Economic Evaluation of Health Technologies.^[@bibr8-2381468318818843]^ The Guidelines represent a major revision from the previous edition, which was published in 2006, to reflect a number of methodological advances that haven taken place in the conduct of economic evaluations and the adoption of a cohesive and appropriate theoretical framework with emphasis on the role of economic evaluation as an input to decision-making processes.^[@bibr9-2381468318818843]^

Within Canada, economic evaluations are conducted primarily to facilitate health care decisions within a publicly funded system. Thus, developers of the guidelines recognized the need to adopt a social decision-making approach as the theoretical paradigm to root the guidelines with the assumption that decision makers within the publicly funded system primarily wish to maximize population health given their budget constraints. Changes within the Guidelines were therefore made to be consistent with the adoption of this paradigm. Significant revisions related to specification of the decision problem, the need for stratified analysis, adopting a theoretically driven discount rate, and the use of probabilistic analysis in the base case: with greater clarity provided in the recommendation for the adoption of a health care system perspective. The objective of this study was to assess the cost-effectiveness of the various pharmacotherapies and identify which treatments are optimal, depending on a woman's age and fracture history and for the subgroup of women who may not be able to tolerate oral bisphosphonates using methods consistent with the revised Canadian guidelines. Thus, analysis was based on defining the relevant decision problem and then cost-effectiveness was assessed with appropriate consideration of uncertainty and variability.

Methods {#section1-2381468318818843}
=======

Decision Problem {#section2-2381468318818843}
----------------

The study was designed to address specific decision problems as required within the recently revised Canadian Guidelines for Economic Evaluation.^[@bibr8-2381468318818843]^ The Guidelines replaced an existing section titled "Study Objective" with a section titled "Decision Problem." This change recognizes that economic evaluations are primarily designed to inform decision making and specification of a decision problem provides a cohesive basis from which to design the research. The decision problem requires specification of the perspective, interventions, metrics (e.g., costs, outcomes) used to compare the interventions and time horizon.

The decision problem that this analysis addresses is which of the currently available pharmacotherapies for osteoporosis a provincial health ministry, as the payer of prescription medications, should cover within a provincial formulary. Analysis incorporates all pharmacotherapies for osteoporosis currently covered by Canadian provincial formularies (alendronate, denosumab, etidronate, risedronate, and zoledronate). As recommended within the Guidelines, analysis includes a no active pharmacotherapy alternative given that in certain patient populations none of the existing pharmacotherapies may be cost-effective. This, in addition, reflects the previous restrictive listing basis for bisphosphonates in Ontario. For all comparators, patients may in addition be taking calcium and/or vitamin D as is typical in osteoporosis clinical studies. The cost-effectiveness of treatments may vary by patient characteristic. A major change in the Guidelines is in the handling of heterogeneity. The cost-effectiveness of an intervention depends on the characteristics of the population for which it is being evaluated. As the existence of heterogeneity will lead to different conclusions, stratified analysis that requires the population to be parsed into smaller, more homogeneous subgroups is required.^[@bibr10-2381468318818843],[@bibr11-2381468318818843]^ The requirement for stratified analysis directly relates to the adoption of the social decision-making viewpoint. Within this study, there are multiple decision problems relating to various patient strata. For illustration, a base case analysis is presented for a cohort of 70- to 74-year-old osteoporotic women with no previous fracture who are able to tolerate oral bisphosphonates. The analysis is conducted, however, for different patients started based on the cohort's initial age group (65--69, 70--74, 75--79, 80--84, 85--89, 90+), fracture history (no previous fracture and previous fracture), and whether or not the individual can tolerate oral bisphosphonates. Intolerance or inability to take oral bisphosphonates is based on the definition from the Ontario Drug Benefit program: either hypersensitivity, abnormalities of the esophagus, or an inability to stand or sit upright for at least 30 minutes.

Given the focus on maximizing population, analysis takes the form of a cost utility analysis with a lifetime time horizon, where outcomes are expressed in terms of quality-adjusted life years (QALYs) with analysis presented in terms of the incremental cost per QALY gained (ICER).^[@bibr8-2381468318818843]^

Based on the preferences of the relevant decision makers, analysis adopts the perspective of the health and social care system in that the costs of health, social services, and long-term care (LTC) are included.^[@bibr8-2381468318818843]^ Adoption of a wider perspective would require that health care decision makers would be willing to trade health gains for benefits to other sectors.

For the base case analysis, costs and benefits were discounted at 1.5% per annum.^[@bibr8-2381468318818843]^ Scenario analysis was conducted with discounting at 0%, 3%, and 5%.^[@bibr8-2381468318818843]^ The revised Guidelines recommended adoption of a social discount rate represented by the real rate of interest on provincial government bonds.^[@bibr12-2381468318818843]^ The revised rate is based on the available empirical evidence.^[@bibr12-2381468318818843]^

Model Design {#section3-2381468318818843}
------------

The analysis was conducted using a decision analytic model for osteoporosis developed based on the most recently available data relevant to the Canadian population. The model used is an update of a model employed in several previous analyses and follows guidelines both for the design of economic models in general and for the design of economic models specific to osteoporosis.^[@bibr8-2381468318818843],[@bibr13-2381468318818843][@bibr14-2381468318818843][@bibr15-2381468318818843]--[@bibr16-2381468318818843]^ The major previous use of the model was in a health technology assessment conducted by CADTH, which examined the cost effectiveness of teriparatide compared to bisphosphonates, which informed provincial decisions relating to this product.^[@bibr14-2381468318818843]^ The model was chosen due to it being independent and to its convergent validity in that it replicates the population-level data available from the data sources. Further details of calibration and validation are provided in an [online appendix](https://journals.sagepub.com/doi/suppl/10.1177/2381468318818843).

Analysis was conducted using a Markov model with 1-year cycle length and a lifetime horizon. The cycle length was chosen based on the unlikeliness of an individual having more than one hip fracture (the event associated with the greatest cost and disutility) in 1 year. The model incorporates the sequelae associated with osteoporosis (e.g., fracture) and the transition of women through different states related to the development of osteoporosis, history of fracture, and residential status. A schematic of the model is provided in [Figure 1](#fig1-2381468318818843){ref-type="fig"}.

![Schematic of Markov model. Schematic illustrates all possible transitions form one cycle to the next. Patients with a hip fracture will either enter into the post-fracture state for 1 year, have a repeat hip fracture, or die. Note that the schematic does not illustrate transitions relating to movement in residential status. Patients can transition from living to the community to living in long-term care from any health state.](10.1177_2381468318818843-fig1){#fig1-2381468318818843}

For the base case the cohort will start the model in the no fracture history state. For each year, a proportion of the cohort can transition into a fracture-related state (hip, wrist, or vertebral), can die, or remain in the no fracture history state. The proportion of the cohort who enter the hip fracture state can in the next cycle either transition into the hip fracture post fracture year 1 state, can die, or can have a repeat hip fracture. The proportion of the cohort in the wrist, vertebral, or hip fracture post year 1 state can transition into any of the fracture event states, die, or enter the previous fracture history state.

The model is populated with relevant transition probabilities and estimates of the costs and utilities associated with each health state^[@bibr3-2381468318818843],[@bibr4-2381468318818843],[@bibr6-2381468318818843],[@bibr7-2381468318818843],[@bibr17-2381468318818843][@bibr18-2381468318818843][@bibr19-2381468318818843][@bibr20-2381468318818843][@bibr21-2381468318818843][@bibr22-2381468318818843][@bibr23-2381468318818843][@bibr24-2381468318818843][@bibr25-2381468318818843][@bibr26-2381468318818843][@bibr27-2381468318818843][@bibr28-2381468318818843][@bibr29-2381468318818843][@bibr30-2381468318818843][@bibr31-2381468318818843][@bibr32-2381468318818843][@bibr33-2381468318818843][@bibr34-2381468318818843]--[@bibr35-2381468318818843]^ ([Table 1](#table1-2381468318818843){ref-type="table"}). Data sources were obtained through review of the available literature and focused on identifying the most recent relevant and appropriate data from a Canadian context.^[@bibr36-2381468318818843]^ Expected values of costs and QALYs for each pharmacotherapy for each patient strata are obtained through probabilistic analysis using Monte Carlo simulation.^[@bibr8-2381468318818843]^ The same technique is used for all strata-specific analyses and all scenario analyses. The model is developed within a Microsoft Excel workbook.

###### 

Parameter Estimates^[a](#table-fn2-2381468318818843){ref-type="table-fn"}^

![](10.1177_2381468318818843-table1)

  Parameter                                                                        Base Value   Probability Distribution       Reference
  -------------------------------------------------------------------------------- ------------ ------------------------------ -----------
  *Natural history data*                                                                                                       
  Relative risk of wrist fracture for each 1 SD decrease in bone density           1.4          Lognormal (1.4, 1.6)           7
  Relative increase of hip fracture for 1 each SD decrease in bone density         2.6          Lognormal (2, 3.5)             7
  Relative increase of vertebral fracture for each 1 SD decrease in bone density   1.8          Lognormal (1.1, 2.7)           7
  Relative risk of hip fracture given previous fracture                            2            Lognormal (1.9, 2.2)           30
  Relative risk of wrist fracture given previous fracture                          1.9          Lognormal (1.3, 2.8)           30
  Relative risk of spine fracture given previous fracture                          2            Lognormal (1.6, 2.4)           30
  Relative risk of hip fracture given living in LTC                                1.5          Lognormal (1.3, 1.7)           31
  Relative risk of mortality post hip fracture and living in LTC                   3.24         Lognormal (2.37, 4.43)         34
  Relative risk of mortality post vertebral fracture                               1.16         Lognormal (1.03, 1.3)          35
  Relative risk of mortality post hip fracture                                     2.87         Lognormal (2.52, 3.27)         5
  Relative risk of mortality given living in LTC                                   1.16         Lognormal (1.1, 1.2)           17
  Average peak bone mass                                                           0.857        Normal (0.857, 0.022)          3
  Bone mass by age                                                                                                             
   50--59                                                                          0.759        Normal (0.759, 0.003)          3
   60--69                                                                          0.695        Normal (0.695, 0.003)          3
   70--79                                                                          0.661        Normal (0.661, 0.003)          3
   80+                                                                             0.593        Normal (0.593, 0.006)          3
  Standard deviation for peak bone mass                                            0.125                                       3
  Standard deviation of bone mass by age                                                                                       
   50--59                                                                          0.119                                       3
   60--69                                                                          0.110                                       3
   70--79                                                                          0.114                                       3
   80+                                                                             0.104                                       3
  Annual probability of vertebral fracture                                                                                     
   50--59                                                                          0.0018       Beta (8.05, 4559.45)           6
   60--69                                                                          0.0015       Beta (4.01, 2626.34)           6
   70--79                                                                          0.0039       Beta (74.44, 18813.8)          6
   80+                                                                             0.0076       Beta (137.16, 17832.5)         6
  Annual probability of wrist fracture                                                                                         
   50--59                                                                          0.0031       Beta (14.08, 4550.05)          6
   60--69                                                                          0.0062       Beta (16.18, 2613.58)          6
   70--79                                                                          0.0086       Beta (309, 35802.22)           6
   80+                                                                             0.0076       Beta (137.16, 17832.5)         6
  Annual probability of hip fracture                                                                                           
   50--59                                                                          0.0003       Beta (2.12, 7215.24)           6
   60--69                                                                          0.0018       Beta (4.84, 2623.84)           6
   70--79                                                                          0.0024       Beta (45.71, 18834)            6
   80+                                                                             0.0064       Beta (115.92, 17861.69)        6
  Proportion of women residing in LTC                                                                                          
   65--69                                                                          0.01         Beta (8,952, 886,248)          32
   70--74                                                                          0.023        Beta (15,235, 647,165)         32
   75--79                                                                          0.057        Beta (29,372, 485,928)         32
   80--84                                                                          0.136        Beta (57,120, 362,880)         32
   \>85                                                                            0.334        Beta (156,446, 311,954)        32
  Proportion of women who are osteoporotic                                                                                     
   50--59                                                                          0.060        Beta (1,196, 1,273)            3
   60--69                                                                          0.183        Beta (1,505, 1,841)            3
   70--79                                                                          0.269        Beta (991, 1,356)              3
   \>80                                                                            0.413        Beta (184, 313)                3
  Mortality in general population (females)                                                                                    
   50--54                                                                          0.0024       Beta (1,368,800, 1,372,100)    33
   55--59                                                                          0.0036       Beta (1,248,734, 1,253,300)    33
   60--64                                                                          0.0057       Beta (1,061,242, 1,067,300)    33
   65--69                                                                          0.0091       Beta (887,055, 895,200)        33
   70--74                                                                          0.0150       Beta (652,462, 662,400)        33
   75--79                                                                          0.0254       Beta (502,196, 515,300)        33
   80--84                                                                          0.0443       Beta (401,409, 420,000)        33
   85--89                                                                          0.0789       Beta (265,173, 287,900)        33
   \>90                                                                            0.1772       Beta (148,523, 180,500)        33
  Proportion of vertebral fractures by treatment requirement                                                                   
   Hospitalized                                                                    0.09         Dirichlet (18, 47, 132)        6
   Physician care                                                                  0.24                                        6
   No treatment                                                                    0.67                                        6
  Proportion of wrist fractures requiring hospitalization                          0.10         Beta (3,697, 33,341)           4
  *Treatment effectiveness*                                                                                                    
  Relative reduction in hip fractures                                                                                          
   Alendronate                                                                     0.59         Lognormal (0.29, 0.99)         26
   Etidronate                                                                      1.02         Lognormal (0.12, 3.71)         26
   Risedronate                                                                     0.78         Lognormal (0.44, 1.31)         26
   Denosumab                                                                       0.67         Lognormal (0.24, 1.46)         26
   Zoledronate                                                                     0.65         Lognormal (0.25, 1.33)         26
  Relative reduction in wrist fractures                                                                                        
   Alendronate                                                                     0.93         Lognormal (0.31, 2.51)         26
   Etidronate                                                                      2.32         Lognormal (0.26, 8.13)         26
   Risedronate                                                                     0.91         Lognormal (0.13, 3.06)         26
   Denosumab                                                                       0.84         Lognormal (0.64, 1.11)         26
  Relative reduction in vertebral fractures                                                                                    
   Alendronate                                                                     0.54         Lognormal (0.4, 0.7)           26
   Etidronate                                                                      0.64         Lognormal (0.31, 1.07)         26
   Risedronate                                                                     0.66         Lognormal (0.48, 0.81)         26
   Denosumab                                                                       0.33         Lognormal (0.23, 0.47)         26
   Zoledronate                                                                     0.30         Lognormal (0.21, 0.43)         26
  *Treatment continuation rates*                                                                                               
  Alendronate (daily)                                                              0.65         Beta (65, 35)                  14
  Etidronate                                                                       0.57         Beta (57, 43)                  14
  Risedronate (daily)                                                              0.62         Beta (62, 38)                  14
  *Relative reduction in noncompliance*                                                                                        
  Once weekly bisphosphonates versus once daily                                    0.719        Lognormal (0.7126, 0.7265)     27
  Denosumab versus bisphosphonates                                                 0.540        Lognormal (0.31, 0.93)         28
   Zoledronate versus denosumab                                                    1.256        Lognormal (1.15, 1.37)         29
  *Cost of health care events*                                                                                                 
  Hip fracture---living in the community                                           50513.75     Gamma (50,514, 401)            18,19
  Hip fracture---living in LTC                                                     19582.77     Gamma (19,583, 403)            18,19
  Hip fracture---women who die following fracture                                  12207.83     Gamma (12,208, 1429)           18,19
  2nd year post hip fracture                                                       5134.32      Gamma (5,134, 210)             18,19
  Wrist fracture---ambulatory                                                      411.40       Gamma (411, 4)                 21
  Wrist fracture---hospitalized                                                    8557.40      Gamma (8,557, 435)             20
  Vertebral fracture---ambulatory                                                  612.40       Gamma (612, 10)                21
  Vertebral fracture---hospitalized                                                12613.40     Gamma (12,613, 559)            20
  No fracture---living in LTC                                                      46301.57     Gamma (46,302, 953)            18,19
  No fracture---living in community                                                9086.38      Gamma (9,086, 72)              18,19
  *Annual drug costs*                                                                                                          
  Alendronate                                                                      153.66       Fixed                          22
  Etidronate                                                                       122.88       Fixed                          22
  Risedronate                                                                      180.31       Fixed                          22
  Denosumab                                                                        825.67       Fixed                          22
  Zoledronate                                                                      371.06       Fixed                          22
  *Utility values*                                                                                                             
  Women aged 65--69---no fracture                                                  0.836        1 − Lognormal (0.164, 0.004)   23
  Women aged 70--74---no fracture                                                  0.824        1 − Lognormal (0.176, 0.004)   23
  Women aged 75--79---no fracture                                                  0.792        1 − Lognormal (0.208, 0.005)   23
  Women aged \>80---no fracture                                                    0.712        1 − Lognormal (0.288, 0.005)   23
  Hip fracture---1st year---utility multiplier                                     0.7          1 − Lognormal (0.3, 0.033)     24
  Hip fracture---2nd year---utility multiplier                                     0.8          1 − Lognormal (0.2, 0.071)     24
  Vertebral fracture---hospitalized---utility multiplier                           0.59         1 − Lognormal (0.41, 0.094)    24
  Wrist---utility multiplier                                                       0.956        1 − Lognormal (0.044, 0.036)   24
  Vertebral fracture---not hospitalized---utility multiplier                       0.909        1 − Lognormal (0.091, 0.043)   25

LTC, long-term care; SD, standard deviation.

Beta and gamma distributions depicted by shape and scale parameters. Dirichlet distribution depicted by concentration parameters. Normal distributions depicted by mean and standard errors. Lognormal distribution depicted by upper and lower bounds of the 95% confidence interval. Costs represent CAN\$ in 2017.

Transition Probabilities {#section4-2381468318818843}
------------------------

Given the structure of the model outlined above, the following transition probabilities are required to allow a simulation of progression through the model: probabilities of hip, wrist, and spine fracture; probability of developing osteoporosis (which is required for calibration purposes as described in the [online appendix](https://journals.sagepub.com/doi/suppl/10.1177/2381468318818843)); probability of being admitted to LTC; and probability of death.

Each of these probabilities will vary by a number of factors. The probability of developing osteoporosis will increase with age.^[@bibr3-2381468318818843]^ The probability of fracture increases with age, residence in LTC, and previous history.^[@bibr6-2381468318818843],[@bibr7-2381468318818843],[@bibr30-2381468318818843],[@bibr31-2381468318818843]^ Admission to LTC increases with age.^[@bibr32-2381468318818843]^ The probability of death increases with age, incidence of fracture, and residence in LTC.^[@bibr5-2381468318818843],[@bibr17-2381468318818843],[@bibr33-2381468318818843][@bibr34-2381468318818843]--[@bibr35-2381468318818843]^ Specific data on probabilities by risk factors were often unavailable. However, data for alternative parameters were available, which allowed computation of the necessary parameters through calibration of the model. Further details of the required calibration and convergent validity of the model are provided in the [online appendix](https://journals.sagepub.com/doi/suppl/10.1177/2381468318818843).

Costs {#section5-2381468318818843}
-----

For each particular state within the decision model, there is an associated estimate of costs (adjusted to 2017 Canadian dollars). Consistent with the adopted perspective, costs relate to the management of fractures, osteoporosis, and subsequent admission to LTC. Scenario analysis included the costs of additional non-osteoporosis health care.

The cost of the health care resources associated with the treatment of a hip fracture in Ontario including immediate acute care, rehabilitation, and institutionalization were obtained from an analysis of health care administrative claims and billing data available at the Institute for Clinical Evaluative Sciences.^[@bibr18-2381468318818843],[@bibr19-2381468318818843]^ The costs of treating a woman with vertebral and wrist fractures that required hospitalization were obtained from an analysis of administrative data held by the Ontario Case Costing Initiative.^[@bibr20-2381468318818843]^ Resource use associated with treating a women with vertebral and wrist fractures that do not require hospitalization were assumed to be the same as from a previous Canadian economic study with current costs obtained from a provincial ministry of health.^[@bibr21-2381468318818843],[@bibr37-2381468318818843],[@bibr38-2381468318818843]^ The proportions of women with these fractures requiring hospitalization was derived from the incidence data of fracture from CaMos and a recent burden of illness study.^[@bibr4-2381468318818843],[@bibr6-2381468318818843]^

Drug costs were obtained from the Ontario Drug Benefit Formulary.^[@bibr22-2381468318818843]^ The yearly cost of each product was obtained by summing the acquisition costs of the medication, an additional 8% markup, and the appropriate number of dispensing fees at a cost of CAN\$8.83 each (4 for alendronate, etidronate, and risedronate; 2 for zoledronate; and 1 for denosumab).

Utilities {#section6-2381468318818843}
---------

Utility values for women with normal health status were obtained by age from the 2014 Canadian Community Health Survey.^[@bibr23-2381468318818843]^ Utility multipliers associated with hip and wrist fractures and vertebral fractures not requiring hospitalization were derived from a systematic review of utility values for fractures^[@bibr24-2381468318818843],[@bibr25-2381468318818843]^ ([Table 1](#table1-2381468318818843){ref-type="table"}).

Treatment-Specific Parameters {#section7-2381468318818843}
-----------------------------

The analysis plan was to adopt the effect of alternative treatments on the risks of fractures from a published network meta-analysis. On review, a number of meta-analyses have been conducted. Given the decision problem that the study is addressing, the meta-analysis would preferably be comprehensive in their inclusion of studies, focused on osteoporotic women and cover at least the comparators of interest. Based on these considerations the most appropriate analysis was conducted by Hopkins and colleagues.^[@bibr26-2381468318818843]^ Analysis adopted estimates derived from a Bayesian indirect treatment comparison with odds ratios converted to relative risks based on prevalence in the placebo groups.^[@bibr26-2381468318818843]^ The Hopkins study covered all major clinical trials in this area; however, it was published prior to the publication of a companion study to the FREEDOM study, which provides the sole evidence of the effect of denosumab on wrist fractures.^[@bibr39-2381468318818843],[@bibr40-2381468318818843]^ This new data were incorporated into the analysis. There is currently no data relating to the impact of zoledronate on wrist fractures, so the same incidence of wrist fractures as with no therapy was assumed.

While the epidemiological data detailed above provide evidence on probabilities across all ages, fracture history, and time; data on treatment effectiveness are restricted to single relative risks relating to the time horizon of the clinical trials. Thus, analysis did make the assumption that there would be a continuance of treatment effect for the duration of therapy; however, given the duration of clinical trials this assumption is likely valid.

Treatment duration was assumed to be a maximum of 5 years. There is evidence that patients experience continued reductions in the risk of fracture after stopping therapy. Thus, the model allows for a fracture set time whereby there is a linear reduction of benefit after the curtailment of therapy up to a set period of time. Base analysis assumed a set time of 2 years with scenario analyses adopting a set time of 0 and 5 years.^[@bibr14-2381468318818843],[@bibr41-2381468318818843][@bibr42-2381468318818843]--[@bibr43-2381468318818843]^

Adherence was incorporated into the model by assuming that a proportion of patients would stop treatment within 12 months of commencement---those who continue would continue for the maximum duration of treatment specified in the analysis. It is necessary to incorporate differential adherence with pharmacotherapies based primarily on their frequency. Data on 12-month adherence to daily alendronate, etidronate, and risedronate were based on data for Ontario.^[@bibr14-2381468318818843]^ Improved adherence for weekly bisphosphonates versus daily was modelled based on relative adherence rates from an analysis of administrative data.^[@bibr27-2381468318818843]^ Improved adherence with denosumab versus weekly bisphosphonates was modelled based on data from a randomized controlled trial.^[@bibr28-2381468318818843]^ The relative adherence with zoledronate versus denosumab was modelled based on data from a recent retrospective observational study.^[@bibr29-2381468318818843]^ Thus, annual adherence rates adopted within the study were 57% for etidronate, 74.8% for weekly alendronate, 72.7% for weekly risedronate, 86.4% for denosumab, and 82.9% for zoledronate.

Analysis {#section8-2381468318818843}
--------

Analysis is presented according to the recent Canadian guidelines.^[@bibr8-2381468318818843]^ Given the objective of maximizing population health, the Guidelines require that costs and outcomes for each intervention must be obtained through probabilistic analysis given that deterministic analysis gives biased estimates when there are nonlinear relationships among input variables and outputs. The Guidelines, therefore, require the use of probabilistic analysis within the base case rather than as probabilistic sensitivity analysis. Thus, the expected values for costs and QALYs were obtained through probabilistic analysis using Monte Carlo simulation.^[@bibr8-2381468318818843]^ All input parameters except drug costs were assumed to be random variables rather than fixed values. Analysis involves re-running the model employing different values for each data input randomly selected from a probability density function that is characterized by the mean value, a measure of dispersion (standard error), and type of distribution. Standard distributions were used for each data element: beta and Dirichlet distributions for probabilities, 1 − lognormal distributions for utility values, lognormal distributions for relative effects, and gamma distributions for cost data.^[@bibr44-2381468318818843]^ Analysis was based on a Monte Carlo simulation whereby 5,000 estimates of the costs and QALYs for each treatment were obtained, which was sufficient to obtain stable estimates of each outcome.

As recommended by the Canadian guidelines, disaggregated results are presented both discounted and undiscounted and a sequential analysis is conducted that requires, first, exclusion of all dominated alternatives and then, second, the estimation sequentially of the incremental cost per QALY gained (ICER) for a less costly comparator compared to the next most costly comparator.

The probability that a particular therapy is optimal for different threshold values for a QALY is illustrated by both a cost-effectiveness acceptability curve and a cost-acceptability frontier.^[@bibr8-2381468318818843]^

As recommended within the revised Guidelines, scenario analyses were conducted to assess if the interpretation of the study results would change with a number of alternative methodological assumptions detailed above.^[@bibr8-2381468318818843]^ This is distinct from deterministic sensitivity analysis whereby the expected value of particular inputs are changed to assess the impact on the study's results and conclusions. The revised Guidelines do not recommend the use of such analyses as they ignore the likelihood of the alternative parameter values and, thus, do not demonstrate the likelihood of the alternative results identified.

A further series of scenario analyses were conducted such that they adopted assumptions similar to those employed in the five previous manufacturer sponsored studies that compared denosumab, risedronate, and alendronate.^[@bibr41-2381468318818843],[@bibr45-2381468318818843][@bibr46-2381468318818843][@bibr47-2381468318818843]--[@bibr48-2381468318818843]^ These studies adopted a number of assumptions favorable toward denosumab: selective and outdated choice of effectiveness data more favorable toward denosumab^[@bibr41-2381468318818843],[@bibr45-2381468318818843][@bibr46-2381468318818843][@bibr47-2381468318818843]--[@bibr48-2381468318818843]^; assuming the impact on mortality of vertebral fractures would be equal^[@bibr48-2381468318818843]^ or greater^[@bibr41-2381468318818843],[@bibr45-2381468318818843][@bibr46-2381468318818843]--[@bibr47-2381468318818843]^ when compared to hip fracture; much higher costs for vertebral fracture^[@bibr41-2381468318818843],[@bibr45-2381468318818843][@bibr46-2381468318818843]--[@bibr47-2381468318818843]^ (in some cases, exceeding those of hip fracture^[@bibr45-2381468318818843],[@bibr46-2381468318818843]^); a lack of clarity on whether the model was fully calibrated especially with respect to mortality^[@bibr41-2381468318818843],[@bibr45-2381468318818843][@bibr46-2381468318818843][@bibr47-2381468318818843]--[@bibr48-2381468318818843]^; and inclusion of the branded cost for risedronate.^[@bibr45-2381468318818843][@bibr46-2381468318818843][@bibr47-2381468318818843]--[@bibr48-2381468318818843]^ A scenario analysis was conducted for women aged 70 to 74 with previous fracture, which partially assessed the impact of these assumptions by adopting alternative relative effects, no calibration of mortality, assuming the cost of vertebral fractures would be 50% of the costs of hip fractures, assuming the impact of an incident vertebral fracture on mortality would be equal to that of hip fracture, and adopting branded costs of risedronate.

Threshold analysis was conducted to ascertain the necessary price reduction for zoledronate and denosumab that would be required for these products to be considered optimal given an assumed maximum willingness to pay for a QALY of CAN\$50,000.^[@bibr49-2381468318818843]^

Results {#section9-2381468318818843}
=======

Analysis for Base Case Population {#section10-2381468318818843}
---------------------------------

For the base case population, denosumab was the most effective treatment in terms of QALYs and life years gained (both discounted and undiscounted; [Table 2](#table2-2381468318818843){ref-type="table"}). However, the gain in discounted QALYs was 0.00015 when compared with zoledronate and 0.0016 when compared with alendronate. Alendronate was associated with lowest lifetime fracture costs and the lowest overall costs of all pharmacotherapies. Alendronate was associated with the lowest number of hip fractures, while denosumab was associated with the lowest number of wrist fractures and denosumab and zoledronate the lowest number of vertebral fractures.

###### 

Disaggregated Lifetime Results for 70- to 74-Year-Old Osteoporotic Women With No Previous Fracture^[a](#table-fn3-2381468318818843){ref-type="table-fn"}^

![](10.1177_2381468318818843-table2)

                                                                                          No Therapy   Alendronate   Etidronate   Risedronate   Denosumab   Zoledronate
  -------------- ------------------------------------------------------------------------ ------------ ------------- ------------ ------------- ----------- -------------
  Undiscounted   Total lifetime costs                                                     \$7,047      \$7,078       \$8,370      \$7,468       \$9,993     \$8,057
                 QALYs                                                                    12.158       12.170        12.139       12.163        12.171      12.171
                 Treatment costs                                                          \$ 0         \$571         \$363        \$653         \$3,469     \$1,534
                 Fracture costs                                                           \$7,047      \$6,506       \$8,007      \$6,815       \$6,524     \$6,523
                 Hip fractures^[b](#table-fn4-2381468318818843){ref-type="table-fn"}^     126.4        117.4         141.2        122.4         118.1       117.9
                 Wrist fractures^[b](#table-fn4-2381468318818843){ref-type="table-fn"}^   162.5        164.4         261.1        175.4         152.2       160.4
                 Spine fractures^[b](#table-fn4-2381468318818843){ref-type="table-fn"}^   153.8        139.9         152.9        144.8         130.6       130.5
                 Life years                                                               16.729       16.737        16.717       16.733        16.737      16.737
  Discounted     Total lifetime costs                                                     \$6,048      \$6,087       \$7,297      \$6,459       \$8,928     \$7,044
                 QALYs                                                                    10.671       10.681        10.654       10.675        10.683      10.682
                 Treatment costs                                                          \$ 0         \$556         \$353        \$635         \$3,371     \$1,492
                 Fracture costs                                                           \$6,048      \$5,532       \$6,943      \$5,823       \$5,557     \$5,552
                 Life years                                                               14.562       14.568        14.552       14.565        14.568      14.568

QALYs (quality adjusted life years), lifetime fractures per 1,000 women. Costs represent CAN\$ in 2017.

Per 1000 women.

When compared to no therapy, alendronate was the only therapy associated with an ICER less than CAN\$50,000 per QALY ([Table 3](#table3-2381468318818843){ref-type="table"}). The ICER for alendronate versus no therapy was \$3,751 per QALY. The ICER for zoledronate versus alendronate was CAN\$666,285 per QALY, and the ICER for denosumab versus zoledronate was CAN\$12.9 million per QALY. Risedronate and etidronate were all dominated by alendronate as they were associated with fewer QALYs and higher costs. The ICER for denosumab versus alendronate was CAN\$1.8 million.

###### 

Sequential Cost Utility Analysis for 70- to 74-Year Old Osteoporotic Women With No Previous Fracture^[a](#table-fn6-2381468318818843){ref-type="table-fn"}^

![](10.1177_2381468318818843-table3)

                             Costs     QALYs    Incremental Cost per QALY Gained Versus No Therapy   Sequential ICER (\$/QALY Gained)
  -------------------------- --------- -------- ---------------------------------------------------- --------------------------------------------------------------------
  *Nondominated therapies*                                                                           
  No therapy                 \$6,048   10.671                                                        
  Alendronate                \$6,087   10.681   \$3,751                                              \$3,751
  Zoledronate                \$7,044   10.682   \$83,503                                             \$666,285
  Denosumab                  \$8,928   10.683   \$238,523                                            \$12,958,077
  *Dominated therapies*                                                                              
  Etidronate                 \$7,297   10.654   Dominated by no therapy                              Dominated by no therapy, alendronate, risedronate, and zoledronate
  Risedronate                \$6,459   10.675   \$85,557                                             Dominated by alendronate
                                                                                                     Subject to extended dominance through no therapy and zoledronate

ICER, incremental cost per QALY gained; QALY, quality-adjusted life year.

Costs represent CAN\$ in 2017.

The interpretation for decision makers of this result would be the following. If their willingness to pay for a QALY was less than CAN\$3,751 per QALY, then for this patient cohort, no therapy would be optimal. If their willingness to pay for a QALY was between CAN\$3,751 and CAN\$666,285 per QALY, alendronate would be optimal. If their willingness to pay for a QALY was between CAN\$666,285 and CAN\$12.9 million per QALY, zoledronate would be optimal. And finally, if their willingness to pay for a QALY was greater than CAN\$12.9 million per QALY, denosumab would be optimal.

[Figure 2a](#fig2-2381468318818843){ref-type="fig"} presents the probability that each therapy is optimal based on the threshold value for a QALY ranging from CAN\$ 0 to CAN\$100,000. For threshold values of a QALY below CAN\$2,165, no therapy has the highest probability of being optimal. For values above CAN\$2,165, alendronate has the highest probability of being optimal; for values above CAN\$12,000 the probability is greater than 50%. At a threshold value of CAN\$50,000 per QALY, the probability that each treatment was optimal was 60.1% for alendronate, 13.8% for risedronate, 10.3% for etidronate, 9.3% for zoledronate, 6.4% for no therapy, and 0.1% for denosumab. At threshold value of a CAN\$100,000, the probabilities were 59.5% for alendronate, 14.1% for risedronate, 12.9% for zoledronate, 9.4% for etidronate, 3.9% for no therapy, and 0.2% for denosumab.

![Cost-effectiveness acceptability curve and cost-effectiveness frontier for base population: (a) Cost-effectiveness acceptability curve; (b) cost-effectiveness frontier.](10.1177_2381468318818843-fig2){#fig2-2381468318818843}

Analysis by Patient Strata {#section11-2381468318818843}
--------------------------

Analysis by different strata found consistent results in terms of their interpretation, although estimated ICERs did vary by a woman's age and fracture history ([Table 4](#table4-2381468318818843){ref-type="table"}). In every strata, alendronate either dominated no therapy or was associated with an ICER of less than CAN\$5,000 per QALY. For all strata, alendronate either dominated zoledronate or the ICER for zoledronate versus alendronate was greater than CAN\$660,000 per QALY. In most strata, alendronate dominated denosumab. In those strata where denosumab was associated with more QALYs than alendronate, the ICER for denosumab versus alendronate ranged from CAN\$1.8 million to CAN\$8.0 million per QALY.

###### 

Sequential Cost Utility Analysis Results for Alternative Patient Populations^[a](#table-fn8-2381468318818843){ref-type="table-fn"}^

![](10.1177_2381468318818843-table4)

  Age                                                                                                          No Previous Fracture                                   Previous Fracture
  ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------
  *Patients able to tolerate oral bisphosphonates*                                                                                                                    
  65--69                                                                                                       ICER for Z v. A = \$1.4 million                        ICER for Z v. A = \$3.1 million
                                                                                                               ICER for D v. Z = \$7.3 million                        NT, E, R, and D subject to dominance
                                                                                                               NT, E, and R subject to dominance                      
  70--74                                                                                                       ICER for A v. NT = \$3,751                             ICER for Z v. A = \$1.6 million
                                                                                                               ICER for Z v. A = \$666,285                            NT, E, R, and D subject to dominance
                                                                                                               ICER for D v. Z = \$13.0 million                       
                                                                                                               E and R subject to dominance                           
  75--79                                                                                                       ICER for Z v. A = \$816,389                            ICER for Z v. A = \$5.2 million
                                                                                                               NT, E, R, and D subject to dominance                   NT, E, R, and D subject to dominance
  80--84                                                                                                       ICER for Z v. A = \$1.1 million                        A optimal as Z, NT, E, R, and D subject to dominance
                                                                                                               NT, E, R, and D subject to dominance                   
  85--89                                                                                                       A optimal as Z, NT, E, R, and D subject to dominance   A optimal as Z, NT, E, R, and D subject to dominance
  90+                                                                                                          ICER for A v. NT = \$2,721                             A optimal as Z, NT, E, R, and D subject to dominance
                                                                                                               ICER for Z v. A = \$1.3 million                        
                                                                                                               E, R, and D subject to dominance                       
  *Patients unable to tolerate oral bisphosphonates* ^[b](#table-fn9-2381468318818843){ref-type="table-fn"}^                                                          
  65--69                                                                                                       ICER for Z v. NT = \$94,365                            ICER for Z v. NT = \$41,374
                                                                                                               ICER for D v. Z = \$7.3 million                        D subject to dominance
  70--74                                                                                                       ICER for Z v. NT = \$83,503                            ICER for Z v. NT = \$40,956
                                                                                                               ICER for D v. Z = \$3.0 million                        D subject to dominance
  75--79                                                                                                       ICER for Z v. NT = \$63,263                            ICER for Z v. NT = \$20,408
                                                                                                               D subject to dominance                                 D subject to dominance
  80--84                                                                                                       ICER for Z v. NT = \$48,142                            ICER for Z v. NT = \$13,484
                                                                                                               D subject to dominance                                 D subject to dominance
  85--89                                                                                                       ICER for Z v. NT = \$51,296                            ICER for Z v. NT = \$17,770
                                                                                                               D subject to dominance                                 D subject to dominance
  90+                                                                                                          ICER for Z v. NT = \$46,842                            ICER for Z v. NT= \$17,796
                                                                                                               D subject to dominance                                 D subject to dominance

A, alendronate; D, denosumab; E, etidronate; ICER, incremental cost per QALY gained; NT, no therapy; QALY, quality-adjusted life year; R, risedronate; Z, zoledronate.

Costs represent CAN\$ in 2017.

Comparison of no therapy, denosumab and zoledronate.

For women unable to tolerate oral bisphosphonates for all strata, zoledronate either dominated denosumab or the ICER for denosumab versus zoledronate was greater than CAN\$7.3 million per QALY. The ICER for zoledronate versus no therapy was below CAN\$50,000 for all women with previous fracture and for those women without a previous fracture aged 80 to 84 and over 90.

Scenario Analysis {#section12-2381468318818843}
-----------------

The conclusions to be drawn from the results of the scenario analysis did not differ from the base analysis ([Table 5](#table5-2381468318818843){ref-type="table"}). The ICER for alendronate versus no therapy remained less than CAN\$8,000 per QALY in all scenarios. The ICER for zoledronate versus alendronate remained greater than \$600,000 for all relevant scenarios. In the scenario analysis using assumptions more favorable to denosumab, the ICER for denosumab versus alendronate for those aged 70 to 74 with a previous fracture fell from CAN\$8 million to CAN\$165,490.

###### 

Results of Scenario Analysis for Base Case Population^[a](#table-fn11-2381468318818843){ref-type="table-fn"}^

![](10.1177_2381468318818843-table5)

  Scenario                                                                                       Sequential Result
  ---------------------------------------------------------------------------------------------- --------------------------------------
  Base case                                                                                      ICER for A v. NT = \$3,751
                                                                                                 ICER for Z v. A = \$666,285
                                                                                                 ICER for D v. Z = \$13.0 million
                                                                                                 E and R subject to dominance
  Set time = 0 years                                                                             ICER for A v. NT = \$7,972
                                                                                                 ICER for Z v. A = \$838,746
                                                                                                 E, R, and D subject to dominance
  Set time = 5 years                                                                             ICER for Z v. A = \$643,327
                                                                                                 NT, E, R, and D subject to dominance
  Discount rate = 0%                                                                             I ICER for A v. NT = \$2,577
                                                                                                 ICER for Z v. A = \$608,211
                                                                                                 ICER for D v. Z = \$8.3 million
                                                                                                 E and R subject to dominance
  Discount rate = 3%                                                                             ICER for A v. NT = \$5,548
                                                                                                 ICER for Z v. A = \$800,853
                                                                                                 ICER for D v. Z = \$47.1 million
                                                                                                 E and R subject to dominance
  Discount rate = 5%                                                                             ICER for A v. NT = \$6,435
                                                                                                 ICER for Z v. A = \$839,796
                                                                                                 E, R, and D subject to dominance
  Inclusion of non-osteoporotic health care costs                                                ICER for A v. NT = \$3,749
                                                                                                 ICER for Z v. A = \$770,725
                                                                                                 ICER for D v. Z = \$4.8 million
                                                                                                 E and R subject to dominance
  Scenario analysis favoring denosumab^[b](#table-fn12-2381468318818843){ref-type="table-fn"}^   ICER for D v. A = \$165,490
                                                                                                 NT and R dominated by A

A, alendronate; D, denosumab; E, etidronate; ICER, incremental cost per QALY gained; NT, no therapy; QALY, quality-adjusted life year; R, risedronate; Z, zoledronate.

Costs represent CAN\$ in 2017.

Analysis compares only no therapy, alendronate, risedronate, and denosumab. Analysis based on assumptions favorable to denosumab relating to calibration, vertebral facture costs, and mortality and treatment effectiveness adopted in previous manufacturer sponsored studies.

Within the base population, based on a threshold of CAN\$50,000 per QALY, a price reduction of 90% would be required for denosumab to be optimal. In certain strata, denosumab would not be optimal even if it had zero cost. In other strata, the required price reduction was at least 90%. For zoledronate, the price reduction would have to be 66% for it to be considered optimal. Across all strata, the necessary price reduction ranged from 66% to 85%.

For woman who are intolerant to oral bisphosphonates, zoledronate was optimal in the majority of strata. For zoledronate to be cost-effective in all strata, the necessary price reduction required was 34%. The required price reduction for denosumab to be optimal in this subgroup of women varied by age and fracture history ranging between 63% and 76%.

Discussion {#section13-2381468318818843}
==========

The aforementioned results suggest that for patients who are able to tolerate oral bisphosphonates, alendronate is the optimal treatment regardless of a woman's age or fracture history. Although alendronate did not dominate denosumab and/or zoledronate in all patient strata, the ICERs for denosumab and zoledronate compared to alendronate were indicative of them not being cost-effective. For patients unable to tolerate oral bisphosphonates, zoledronate can be considered optimal for a proportion of women as it was associated with an ICER of less than CAN\$50,000 in the majority of strata (for women with no previous fracture aged 80--84 or over 90 and for all women with a previous fracture). Denosumab was either dominated by zoledronate (for women with no previous fracture aged over 75 and for all women with a previous fracture) or had an ICER compared to zoledronate that was indicative of it not being cost-effective (for women with no previous fracture aged under 75).

Based on the available literature, this is the first economic evaluation comparing such a wide range of osteoporotic treatments that is independent of manufacturer sponsorship. There are a number of publications that have suggested that manufacturer-sponsored economic evaluations may be susceptible to bias.^[@bibr50-2381468318818843],[@bibr51-2381468318818843]^ Five manufacturer-sponsored studies were identified and two independent studies---one comparing denosumab and alendronate and another comparing anabolic drugs (abaloparatide and teriparatide) to no therapy.^[@bibr41-2381468318818843],[@bibr45-2381468318818843][@bibr46-2381468318818843][@bibr47-2381468318818843]--[@bibr48-2381468318818843],[@bibr52-2381468318818843],[@bibr53-2381468318818843]^

The results of this analysis are in contrast to the five previous studies of denosumab funded by the manufacturer. Chau and colleagues reported an incremental cost per QALY gained of \$60,266 (2010 CAN\$) for denosumab versus alendronate for a base case of 72-year-old women with previous fracture.^[@bibr41-2381468318818843]^ Jönsson and colleagues reported an incremental cost per QALY gained of €27,090 (2009 euros) for 71-year-old women (34% assumed to have a previous fracture).^[@bibr45-2381468318818843]^ Darbà and colleagues reported an incremental cost per QALY gained of €16,294 (2013 euros) for 65-year-old women (28% with previous fracture).^[@bibr46-2381468318818843]^ Parthan and colleagues reported an ICER of \$85,060 per QALY for denosumab versus alendronate for a cohort of 72-year-old osteoporotic women---23% with prevalent vertebral fracture (2012 US\$). Finally, Hiligsmann and Reginster reported an ICER of €14,166 per QALY for a 70-year-old osteoporotic women with previous vertebral fracture (2009 euros).^[@bibr48-2381468318818843]^

All of the above findings contrast with our result that denosumab was either dominated by alendronate or was associated with a much higher ICER. The difference in results between the studies and the current analysis may be due to four issues. First, it is unclear that the manufacturer-sponsored studies adequately accounted for calibration especially in relation to mortality. Second, the studies used similar estimates of effectiveness that did not incorporate all older clinical trials for oral bisphosphonates. The choice of effectiveness data favored denosumab especially in terms of reductions in hip fractures. Third, the studies made the assumption that the increase in mortality associated with vertebral fractures was either greater or equal to that associated with hip fractures. Finally, the studies assumed much higher costs associated with vertebral fractures, in some instances exceeding those of hip fractures.

A scenario analysis attempted to address these issues by assuming efficacy as used within the manufacturer sponsored studies; equal mortality associated hip and vertebral fractures; higher costs associated with vertebral fractures; and by not calibrating mortality data. This analysis found an ICER for denosumab versus alendronate of \$165,490: closer to the various manufacturers' estimates.

An independent analysis by Karnon and colleagues found that denosumab was not cost-effective compared to alendronate with an estimated ICER for denosumab versus alendronate of \$246,749 per QALY (AUS\$ unknown date).^[@bibr52-2381468318818843]^ This analysis differed from the current analysis in two ways. First, it modelled the effectiveness of treatment through changes in BMD rather than fracture prevention. Second, it assumed a much lower cost of denosumab based on current Australian funding of denosumab which fixed the cost to be similar to branded alendronate.

A recent independent study from the Institute of Clinical and Economic Review focused on anabolic therapies for postmenopausal osteoporosis.^[@bibr53-2381468318818843]^ Thus, given the comparators, the results are not directly related to the current study. However, the methods adopted and the assumptions made in the current study are consistent with approach adopted by this independent report.

In Ontario under the Ontario Drug Formulary, funding for denosumab is restricted to women who experience significant decline in BMD after 1 year continuous bisphosphonate therapy or are unable to tolerate oral bisphosphonates due to either hypersensitivity or abnormalities of the esophagus. For both criteria, woman must also meet two of three criteria: age over 75, be osteoporotic (a BMD *T*-score less than or equal to −2.5), and/or have a previous osteoporotic fracture. Funding for zoledronate is restricted to women who are unable to tolerate oral bisphosphonates due to the same reasons and who meet the same criteria as for denosumab. Despite these limited access criteria, expenditure on denosumab in 2015--2016 in Ontario was CAN\$34.79 million---suggesting the equivalent of over 47,000 annual users in Ontario.^[@bibr54-2381468318818843]^ For risedronate, annual expenditure of the data suggested 88,000 users. Data for alendronate were unavailable for 2015--2016 but for 2013--2014, the data suggests over 110,000 users.^[@bibr55-2381468318818843]^

There is the potential that provincial drug plans may have negotiated lower prices for zoledronate and denosumab though those prices remain confidential. Threshold analysis was conducted and demonstrated that the costs of denosumab and zoledronate needed to be reduced substantially to allow these therapies to become optimal for treating all osteoporotic women. When limiting these products to those unable to tolerate oral bisphosphonates, the current costs of zoledronate is such that it is cost-effective for treating a high proportion of women who fall into this indication. However, the cost of denosumab would need to be reduced substantially for it to be cost-effective even in this small subgroup of women.

It is unclear what the true incidence of intolerance to oral bisphosphonates is. In one randomized controlled trial of once weekly alendronate compared to placebo, the percentage of patients reporting an upper gastrointestinal tract adverse event was lower for alendronate patients (11%) than for placebo (13%).^[@bibr56-2381468318818843]^ The probability that a patient on alendronate would discontinue due to such an event was 3%. These findings suggest that only a small percentage of osteoporotic women fall in to this subgroup.

The recent Canadian guidelines are consistent in clearly recommending health care system perspective as the primary analysis based on its relevance to the decision problem. Thus, for the current analyses, it would not be appropriate to consider the societal perspective as it has been consistently shown that this is not considered of relevance to provincial decision makers. Adoption of the societal perspective assumes that health care decision makers would be willing to trade health gains for benefits to other sectors. Thus, the choice of the health care system perspective is not a limitation as such. It should be noted that as the population of interest is greater than 65 the likely impacts on productivity will be minimal and results from the societal perspective would likely be similar to current results.

The current study does, however, have a number of limitations. First, there is a lack of head to head clinical trials and thus analysis relied on effectiveness data from an indirect treatment comparison of randomized controlled trials the majority of which were placebo controlled rather than active comparators. It would be beneficial that future novel treatments for osteoporosis are compared with current existing therapies especially oral bisphosphonates, which are available in low-cost generic format.

Second, analysis used fracture prevalence data from 2009. It is assumed that prevalence has not changed greatly but a re-analysis should be conducted if more temporaneous data become available.

Third, a detailed stratified analysis is conducted as per the recent Canadian guidelines for economic evaluation. For many data elements strata-specific data are available but for some the assumption needed to be made that data did not vary by strata. That is a limitation, and should further strata-specific data become available then a reanalysis would be justified.

Fourth, for zoledronate, the effect on wrist fractures is not reported in any clinical trial for postmenopausal women. This is surprising as such data may have been collected within the clinical trials but not reported. Within this analysis it was assumed that the risk of wrist fracture with zoledronate was the same as for no therapy.

Additionally, analysis is based on the assumption that individuals will not undergo sequential treatment with oral bisphosphonates. Thus, the decision problem relates to what would be the optimal treatment for osteoporosis rather than the optimal sequence of treatments. The results of the analysis suggest that the only oral bisphosphonate likely to be cost-effective is alendronate. Furthermore, the analysis suggest that for those unable to tolerate oral bisphosphonates only zoledronate is cost-effective in those with previous fracture. Thus, if sequencing of treatment was necessary for patients who experience a fracture on therapy, the optimal sequence of treatments for postmenopausal osteoporosis is likely to be alendronate followed by zoledronate post fracture.

Finally, costs were based on the most recent available Canadian data, and drug costs were obtained from the Ontario drug formulary. This may be seen as a limitation. Although drug costs may vary by provincial formulary, it is unlikely that list prices would vary substantially enough to alter the conclusions of this analysis.

In conclusion, this study demonstrated that, based on the currently available data, treatment with alendronate is the optimal strategy for women who are able to tolerate oral bisphosphonates. For women unable to tolerate oral bisphosphonates, zoledronate is optimal for a high proportion of women. The required price reductions to lead to denosumab being cost-effective in either group were substantial.

Thus, the policy implications from this analysis is that denosumab should not be covered under provincial drug formularies for the general osteoporotic population unless substantial price reductions can be negotiated. Zoledronate should be covered but this should continue to be restricted to women who are truly intolerant to weekly oral bisphosphonate therapy.
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